Junshi Biosciences Announces the Phase 3 Study of JS005 (IL-17A) for the Treatment of Moderate to Severe Plaque Psoriasis Met Primary Endpoints
SHANGHAI, Sept. 07, 2025 (GLOBE NEWSWIRE) -- Shanghai Junshi Biosciences Co., Ltd…
Vagaro Research Shows 90% of Service Professionals Face High Stress & Burnout
SAN FRANCISCO--(BUSINESS WIRE)--New data from the 2025 Vagaro Vantage Report reveals higher…
